Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility

References

• Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692–699.
   PubMed Web of Science ®Google Scholar
• Veeger NJ, Piersma-Wichers M, Tijssen JG, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Brit J Haematol. 2005;128:513–519.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523–526.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199–205.
   PubMed Web of Science ®Google Scholar
• Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689–696.
   PubMed Web of Science ®Google Scholar
• Pai M, Evans NS, Shah SJ, et al. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res. 2011;128:422–430.
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792–1802.
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119:2051–2057.
   PubMed Web of Science ®Google Scholar
• Rosendaal FR. Statins and venous thrombosis: a story too good to be true? PLoS Med. 2012;9:e1001311.
   PubMed Web of Science ®Google Scholar
• Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32:51–63.
   PubMedGoogle Scholar
• Thomsen RW. The lesser known effects of statins: benefits on infectious outcomes may be explained by “healthy user” effect. BMJ. 2006;333:980–981.
   PubMed Web of Science ®Google Scholar
• Lijfering WM, Flinterman LE, Vandenbroucke JP, et al. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost. 2011;37:885–896.
   PubMed Web of Science ®Google Scholar
• Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003 Nov 1;158:915–920.
   PubMed Web of Science ®Google Scholar
• Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175:250–262.
   PubMed Web of Science ®Google Scholar
• Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996;313:652–659.
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Horvath-Puho E, Søgaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost. 2009;7:521–528.
   PubMed Web of Science ®Google Scholar
• Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. 1980; 303:1038–1041.
   PubMed Web of Science ®Google Scholar
• Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:1538–1541.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA. 1993;270:742–744.
   PubMed Web of Science ®Google Scholar
• Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67:99–109.
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851–1861.
   PubMed Web of Science ®Google Scholar
• Rahimi K, Bhala N, Kamphuisen P, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med. 2012;9:e1001310.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565.
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.
   PubMed Web of Science ®Google Scholar
• Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117:93–102.
   PubMed Web of Science ®Google Scholar
• Horvei LD, Grimnes G, Hindberg K, et al. C-reactive protein, obesity, and risk of arterial and venous thrombosis. J Thromb Haemost. 2016;14:1561–1571. doi:10.1111/jth.13369
   PubMed Web of Science ®Google Scholar
• Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435–1441.
   PubMed Web of Science ®Google Scholar
• Zhang W-H, Deneux-Tharaux C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
   PubMed Web of Science ®Google Scholar
• Borissoff JI, Spronk HM, Ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364:1746–1760.
   PubMed Web of Science ®Google Scholar
• Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost. 2007;5:270–275.
   PubMed Web of Science ®Google Scholar
• Borissoff JI, Otten JJ, Heeneman S, et al. Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS One. 2013;8:e55784.
   PubMed Web of Science ®Google Scholar
• Borissoff JI, Heeneman S, Kilinç E, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010;122:821–830.
   PubMed Web of Science ®Google Scholar
• Seehaus S, Shahzad K, Kashif M, et al. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation. 2009;120:774–784.
   PubMed Web of Science ®Google Scholar
• With Notø AT, Mathiesen EB, Østerud B, et al. Increased thrombin generation in persons with echogenic carotid plaques. Thromb Haemost. 2008;99:602–608.
   PubMed Web of Science ®Google Scholar
• Kalz J, Ten Cate H, Spronk HM. Thrombin generation and atherosclerosis. J Thromb Thrombolysis. 2014;37:45–55.
   PubMed Web of Science ®Google Scholar
• Cai JM, Hatsukami TS, Ferguson MS, et al. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation. 2002;106:1368–1373.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guallar E, Qiao Y, et al. Is carotid intima-media thickness as predictive as other noninvasive techniques for the detection of coronary artery disease? Arterioscler Thromb Vasc Biol. 2014;34:1341–1345.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010;121:1896–1903.
   PubMed Web of Science ®Google Scholar
• Brækkan SK, Hald EM, Mathiesen EB, et al. Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study. Arterioscler Thromb Vasc Biol. 2012;32:487–491.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg IM, Mahmoodi BK, Gansevoort RT, et al. Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study. Thromb Haemost. 2012;108:923–929.
   PubMed Web of Science ®Google Scholar
• Ramcharan AS, Van Stralen KJ, Snoep JD, et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost. 2009;7:514–520.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Folsom AR, Lutsey PL, Astor BC, et al. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost. 2009;102:615–619.
   PubMed Web of Science ®Google Scholar
• Quist-Paulsen P, Naess IA, Cannegieter SC, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica. 2010;95:119–125.
   PubMed Web of Science ®Google Scholar
• Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol. 2010;30:1672–1678.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators. Circulation. 1999;100:230–235.
   PubMed Web of Science ®Google Scholar
• Zolcinski M, Cieśla-Dul M, Potaczek DP, et al. Atorvastatin favourably modulates proinflammatory cytokine profile in patients following deep vein thrombosis. Thromb Res. 2013;132:e31–5.
   PubMed Web of Science ®Google Scholar
• Puccetti L, Santilli F, Pasqui AL, et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis. 2011;214:122–128.
   PubMed Web of Science ®Google Scholar
• Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117:1400–1710.
   PubMed Web of Science ®Google Scholar
• Joglekar MV, Ware J, Xu J, et al. Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl(3)-induced occlusive thrombus formation in the inferior vena cava of mice. Platelets. 2013;24:205–212.
   PubMed Web of Science ®Google Scholar
• Pignatelli P, Carnevale R, Pastori D, et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation. 2012;126:92–103.
   PubMed Web of Science ®Google Scholar
• Weber M, Gerdsen F, Gutensohn K, et al. Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism. Thromb Res. 2002;107:325–328.
   PubMed Web of Science ®Google Scholar
• Biedermann JS, Cannegieter SC, Roest M, et al. Platelet reactivity in patients with venous thrombosis who use rosuvastatin: a randomized controlled clinical trial. J Thromb Haemost. 2016;14:1404–1409.
   PubMed Web of Science ®Google Scholar
• Israels SJ. Laboratory testing for platelet function disorders. Int J Lab Hematol. 2015;37:18–24.
   PubMed Web of Science ®Google Scholar
• Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 1997;17:265–272.
   PubMed Web of Science ®Google Scholar
• Violi F, Calvieri C, Ferro D, et al. Statins as antithrombotic drugs. Circulation. 2013;127:251–257.
   PubMed Web of Science ®Google Scholar
• Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost. 2014;111:392–400.
   PubMed Web of Science ®Google Scholar
• Undas A, Celinska-Löwenhoff M, Brummel-Ziedins KE, et al. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2005;25:1524–1525.
   PubMed Web of Science ®Google Scholar
• Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:2248–2253.
   PubMed Web of Science ®Google Scholar
• Zolcinski M, Ciesla-Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost. 2012;107:1180–1182.
   PubMed Web of Science ®Google Scholar
• Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999;33:1294–1304.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Serban C, Ursoniu S, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115:520–532.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Serban C, Mikhailidis DP, et al. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost. 2015;114:546–557.
   PubMed Web of Science ®Google Scholar
• Barreto AC, Maeda NY, Soares RP, et al. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. Braz J Med Biol Res. 2008;41:657–663.
   PubMed Web of Science ®Google Scholar
• Adams NB, Lutsey PL, Folsom AR, et al. Statin therapy and levels of hemostatic factors in a healthy population: the multi-ethnic study of atherosclerosis. J Thromb Haemost. 2013;11:1078–1084.
   PubMed Web of Science ®Google Scholar
• Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221–228.
   PubMedGoogle Scholar
• Kraaijenhagen RA, In ‘T Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83:5–9.
   PubMed Web of Science ®Google Scholar
• Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457–462.
   PubMed Web of Science ®Google Scholar
• Timp JF, Lijfering WM, Flinterman LE, et al. Predictive value of factor VIII levels forrecurrent venous thrombosis: results from the MEGA follow-up study. J Thromb Haemost. 2015;13:1823–1832.
   PubMed Web of Science ®Google Scholar
• Cushman M. A new indication for statins to prevent venous thromboembolism? Not yet. J Thromb Haemost. 2009;7:511–513.
   PubMed Web of Science ®Google Scholar
• Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630–1636.
   PubMed Web of Science ®Google Scholar
• Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). JThromb Haemost. 2012;10:1019–1025.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Scarvelis D, Kahn SR, et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multi-national cohort. Thromb Res. 2016;143:152–158.
   PubMed Web of Science ®Google Scholar